Gilead Sciences Commits to Veeva Vault CRM
Next generation CRM with deep capabilities and agentic AI PLEASANTON, Calif., Sept. 10, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV)...
COVID-19
STAT Marks 10 Years of Reporting from the Frontiers of Health and Medicine
Award-winning journalism has drawn millions of loyal readers BOSTON, Sept. 9, 2025 /PRNewswire/ -- STAT launched 10 years ago with a...
STAT Marks 10 Years of Reporting from the Frontiers of Health and Medicine
Award-winning journalism has drawn millions of loyal readers BOSTON, Sept. 9, 2025 /PRNewswire/ -- STAT launched 10 years ago with a...
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage...
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September...
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology,...
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo...
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Services PMI® at 52%; August 2025 ISM® Services PMI® Report
Business Activity Index at 55%; New Orders Index at 56%; Employment Index at 46.5%; Supplier Deliveries Index at 50.3% TEMPE, Ariz.,...
Hemostemix’s VesCell.Health Launched in Florida
Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among...
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease...
Hyro Launches Proactive Px™ with AI Agent to Help Healthcare Organizations Handle Coverage Disruption Caused by OBBBA
The complementary AI agent will conduct first-of-its-kind automated outreach on behalf of health systems via voice and SMS for ACA...
Howie’s 17+ Years After VesCell(TM): Following Hemostemix’s Heart Patients
Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Hyperfine Receives CE Mark and UKCA Approval for Optive AI™ Software, Expanding Global Commercialization of Latest AI-Powered Imaging Software
Approvals mark a major milestone and bring the most advanced image quality to date to Swoop® system users in European...
Hyperfine Receives CE Mark and UKCA Approval for Optive AI™ Software, Expanding Global Commercialization of Latest AI-Powered Imaging Software
Approvals mark a major milestone and bring the most advanced image quality to date to Swoop® system users in European...
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its...
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to...